Gene-Editing Stocks Plunge on Editas CEO Exit, Crispr Downgrade

(Bloomberg) -- Gene-editing companies are among the worst-performing biotechnology stocks Tuesday after Editas Medicine’s chief executive officer left and Citi questioned Crispr Therapeutics’ data.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.